COMPARISON
Glucagon vs Insulin degludec
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Glucagon is authorised or registered in 10 and Insulin degludec in 10 of the 10 registers read. Glucagon: highest phase Phase 4 (after approval). Insulin degludec: highest phase Phase 4 (after approval). 19 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Glucagon | Insulin degludec | |
|---|---|---|
| Registered trials differs | 1514 clinicaltrials.gov · 2026-10-03 | 255 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Glucagon openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Xultophy 100/3.6 openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2019-12-16 ema · 2026-10-03 | 2013-01-20 ema · 2026-10-03 |
| ATC code differs | H04AA01 ema · 2026-10-03 | A10AE06 ema · 2026-10-03 |
LEGAL STATUS
Approval in each country read
| Country | Glucagon | Insulin degludec | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
19 registered trials include both
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study ACTIVE_NOT_RECRUITING · updated 2026-08-13 |
|---|---|
| NCT04952779 | Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Dia COMPLETED · updated 2025-12-31 |
| NCT05218915 | Basal Plus GLP1-ra on Glycemic Variability in CKD COMPLETED · updated 2024-12-03 |
| NCT04666987 | A Research Study Looking at Long-term Blood Sugar Control in People With Type 2 Diabetes Being Treated With Xultophy® in a Real-world Setting in Italy COMPLETED · updated 2024-04-03 |
| NCT03737240 | IDegLira HIGH Trial COMPLETED · updated 2023-09-08 |
| NCT05161429 | BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes UNKNOWN · updated 2023-06-22 |
| NCT03172494 | A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antid COMPLETED · updated 2022-12-14 |
| NCT03882970 | A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes COMPLETED · updated 2022-01-19 |
| NCT03823339 | A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates COMPLETED · updated 2021-09-22 |
| NCT02607306 | A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. COMPLETED · updated 2021-04-09 |
| NCT04034524 | Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin UNKNOWN · updated 2020-07-09 |
| NCT03292185 | A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjec COMPLETED · updated 2019-11-18 |
| NCT01676116 | The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD T COMPLETED · updated 2019-01-03 |
| NCT02738151 | Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug( COMPLETED · updated 2018-09-14 |
| NCT01336023 | Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec COMPLETED · updated 2018-02-19 |
| NCT01664247 | The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification COMPLETED · updated 2017-09-25 |
| NCT01388361 | Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin COMPLETED · updated 2017-03-06 |
| NCT00983021 | Safety and Tolerability of NN9068 in Healthy Male Volunteers COMPLETED · updated 2017-02-08 |
| NCT01319240 | Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects COMPLETED · updated 2015-10-02 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.